Blacks More Likely to Have Disseminated Manifestations of Lyme Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 14, 2023 -- Black patients are more likely to be diagnosed with disseminated manifestations of Lyme disease (LD) and experience longer time to appropriate treatment, according to a research letter published online Dec. 12 in JAMA Network Open.
Samuel J. Starke, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues conducted a cross-sectional study to analyze data from patients with suspected untreated or posttreatment LD. Initial LD presentations were classified as erythema migrans (EM) only; disseminated neurologic, cardiac, or joint disease; or symptoms only, without objective signs. Racial distributions were examined across groups.
The final sample included 1,395 patients; differences were most marked among Black patients, and subsequent analyses compared 1,334 Black and White patients. The researchers found that Black patients had 4.93 times the odds of disseminated disease compared with the EM-only group, after controlling for age and gender. Men also had higher odds of disseminated disease (odds ratio, 1.61). The odds of being in the symptoms-only group were independently higher for Black patients (odds ratio, 2.07), for women (odds ratio, 1.39), and with younger age (odds ratio, 1.12 per 10 years). Compared with White patients, Black patients had a significantly longer median time to appropriate antibiotic treatment (35 versus seven days); this was significant among patients with EM (26 versus four days).
"We identified several racial differences in the clinical presentation and treatment of LD," the authors write. "Efforts are needed to increase patient and clinician awareness to ensure equitable reductions in disease burden."
One author had a patent issued for deep learning for Lyme disease diagnosis.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.